Emmanuelle Preaud
An Affiliate Of Merck KGaA, Darmstadt, Germany, 37 Rue Saint Romain
Lyon, France
Lyon, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: June 24, 2021
Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Journal: Human vaccines & immunotherapeutics
Published: May 02, 2015
Cost Effectiveness Analysis of A Vaccination Programme for the Prevention of Herpes Zoster and Post-Herpetic Neuralgia in Adults Aged 65 and Over in Norway.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Cost-Effectiveness Analysis of a Shingles Vaccination Program to Prevent Herpes Zoster And Post- Herpetic Neuralgia in the Spanish Setting.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
The humanistic, economic and societal burden of herpes zoster in Europe: a critical review.
Journal: BMC public health
Published: September 01, 2014
Annual public health and economic benefits of seasonal influenza vaccination: a European estimate.
Journal: BMC public health
Published: November 13, 2013
Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review.
Journal: Journal of medical economics
Published: April 10, 2013
Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: March 30, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026